Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARFONAD vs ALPHALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.
ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Controlled hypotension during surgery,Hypertensive emergencies
Hypertension (FDA-approved),Attention deficit hyperactivity disorder (ADHD) (off-label),Opioid withdrawal (off-label)
Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.
500 mg orally once daily
Terminal elimination half-life is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, leading to ultrashort duration.
Terminal half-life 12-15 hours (healthy adults); prolonged to 24-30 hours in renal impairment (Cr Cl <30 m L/min)
Primarily metabolized by plasma pseudocholinesterase (butyrylcholinesterase); also undergoes hepatic metabolism.
Primarily hepatic via cytochrome P450 isoenzyme CYP2D6; metabolites are excreted renally.
Primarily renal excretion of unchanged drug (approximately 30-50%) with the remainder metabolized; minimal biliary/fecal elimination.
Renal excretion (70% unchanged); fecal/biliary (20%); metabolism (10%)
Approximately 50% bound to plasma proteins, primarily albumin.
98% bound primarily to albumin
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
0.3-0.5 L/kg; reflects limited extravascular distribution consistent with high protein binding
Only administered intravenously; oral bioavailability is negligible due to rapid hydrolysis.
Oral: 80-90% (first-pass metabolism ~10-20%); IM: 95-100%
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to potential for accumulation.
e GFR 30-59 m L/min: 250 mg orally once daily; e GFR 15-29 m L/min: 125 mg orally once daily; e GFR <15 m L/min: 125 mg orally every 48 hours
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 250 mg orally once daily; Child-Pugh Class C: 125 mg orally once daily
Not recommended in pediatric patients due to lack of safety and efficacy data.
10-15 mg/kg orally once daily, not to exceed 500 mg/day
Initiate at lower end of dosing range (0.5 mg/min) and titrate slowly due to increased sensitivity to hypotension and reduced metabolic clearance.
Initiate at 250 mg orally once daily; titrate based on renal function
None.
Avoid abrupt discontinuation; rapid withdrawal can cause rebound hypertension, anxiety, and, in severe cases, hypertensive encephalopathy or stroke.
May cause profound hypotension; monitor blood pressure closely.,Use with caution in patients with hypovolemia, myocardial ischemia, or cerebrovascular insufficiency.,Can cause histamine release leading to bronchospasm; avoid in patients with asthma.,May cause pupillary dilation and cycloplegia; use caution with glaucoma.,Can inhibit plasma pseudocholinesterase; prolonged effect in patients with atypical pseudocholinesterase.
May cause sedation, dizziness, and orthostatic hypotension. Use caution in patients with cerebrovascular or cardiovascular disease. Monitor blood pressure regularly. Do not administer with other alpha-2 agonists.
Hypersensitivity to trimethaphan or any component,Severe hypotension or shock,Myocardial infarction or coronary insufficiency,Uncompensated heart failure,Asthma or severe chronic obstructive pulmonary disease,Glaucoma (narrow-angle),Pregnancy (category C; may cause fetal harm)
Hypersensitivity to ALPHALIN or any component; concurrent use with other alpha-2 adrenergic receptor agonists; severe bradycardia or heart block (unless paced).
No specific food interactions; however, avoid large meals before surgery as general fasting guidelines apply.
No specific food interactions documented. However, avoid alcohol for 24 hours post-administration due to additive hypotensive effects. Grapefruit juice may potentiate alpha-blocker effects; avoid concurrent use.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies. Potential for fetal harm due to maternal hypotension and reduced uteroplacental perfusion. First trimester: theoretical risk of teratogenicity due to altered hemodynamics, but no specific malformations reported. Second and third trimesters: risk of fetal hypoxia, bradycardia, and acidosis due to maternal hypotension. Avoid use in pregnancy unless clearly needed.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.
No data on excretion in human milk. M/P ratio unknown. Caution: due to potential for ganglionic blockade in infant, consider benefit vs risk. A decision should be made to discontinue nursing or discontinue drug.
Contraindicated during breastfeeding due to high transfer into breast milk; M/P ratio > 1.5.
Pregnancy may alter pharmacokinetics; however, specific dose adjustments for Arfonad are not established. Use lowest effective dose. Rapid titration with continuous monitoring to achieve desired hypotensive effect while avoiding excessive hypotension and fetal compromise.
Dose reduction by 30-50% recommended in second and third trimesters due to increased clearance.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension during surgery. Monitor blood pressure closely as it can cause profound hypotension. Tachyphylaxis develops rapidly. Use with caution in patients with renal impairment, as drug accumulation may occur. Administer via continuous IV infusion, titrating to desired effect. Have vasopressors (e.g., phenylephrine) ready to reverse hypotension. Arfonad can release histamine, so monitor for bronchospasm in asthmatics.
ALPHALIN is a high-potency alpha-blocker indicated for hypertensive emergencies. Administer as a slow IV bolus over 5 minutes to avoid severe hypotension. Monitor blood pressure every 2 minutes during infusion. Have intravenous fluids and vasopressors ready. Contraindicated in patients with known hypersensitivity, acute myocardial infarction, or history of orthostatic hypotension.
You will receive this medication only in the hospital, typically during surgery.,Your blood pressure will be closely monitored throughout the infusion.,Report any difficulty breathing, hives, or palpitations immediately.,This medication may cause blurred vision, dizziness, or dry mouth; avoid sudden position changes.,Do not stop the infusion abruptly; it will be tapered by your healthcare team.
This medication is given intravenously in a hospital setting only.,You will have continuous blood pressure monitoring during administration.,Report any dizziness, chest pain, or difficulty breathing immediately.,After treatment, rise slowly from sitting or lying to prevent fainting.,Avoid alcohol for 24 hours after treatment to prevent blood pressure drop.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARFONAD vs ALPHALIN, answered by our medical review team.
ARFONAD is a Ganglionic Blocker that works by Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.. ALPHALIN is a Vitamin A Supplement that works by ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARFONAD and ALPHALIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARFONAD is: Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.. The standard adult dose of ALPHALIN is: 500 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARFONAD and ALPHALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARFONAD is classified as Category C. Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies.. ALPHALIN is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.